In melanoma and other tumors, resistance to kinase inhibitors like BRAFi and MEKi is often mediated by an abrogation of intrinsic apoptosis signaling pathways—namely by downregulation of BH3-only proteins or by induction and activation of BCL-2 family members like BCL-2, BCL-XL, BFL-1, and MCL-1 [27]. Here, BCL2 is linked to melanoma.